"id:ID","id","name","uuid","documentVersion","bcCategories","label","studyDesignRationale","description","studyInvestigationalInterventions","studyEstimands"
"820","StudyDesign_1","Study Design 1","20773c56-c601-430b-bd5f-ca9741e8c31e","","[]","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","[]","[]"
